INNO.CN - InnoCan Pharma Corporation
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.2500 |
| Open | 0.2700 |
| Bid | 0.2600 x N/A |
| Ask | 0.2800 x N/A |
| Day's Range | 0.2700 - 0.2800 |
| 52 Week Range | 0.1950 - 0.6000 |
| Volume | |
| Avg. Volume | 16,367 |
| Market Cap | 70.506M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
CNW GroupInnocan Pharma Reports Q1 2023 Results including US$1.3M Increase in Revenues Compared to Q1 2022
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to report its financial results for the three months ended March 31, 2023.
- CNW Group
Innocan Pharma Reports Success in a Pre-Clinical Trial of a Liposomal-CBD Injection on a Paralyzed Goat
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a leading pharmaceutical and biotech company, is pleased to announce the successful treatment of Billy, a 4-year-old neutered male goat, with a liposomal-CBD injection in a pre-clinical trial. The innovative therapy provided much-needed relief to the animal, born with neurological deficits and scoliosis, resulting in hind-limb paralysis and fore-limb deformity. Scientific research indicates that the suc
CNW GroupInnocan Pharma Announces 5000 Units Sale and Expansion to Lithuania, Latvia & Estonia Markets
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the entering into of a wide-scope commercial distribution agreement with UAB Medexy ("UAB Medexy") (the "Distribution Agreement").
- CNW Group
Innocan Pharma Reports Annual 2022 Results with USD 2.6M in Revenue
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its audited financial results for the year ended December 31,2022.
- CNW Group
Innocan Reports Novel Cannabinoid Delivery Platform Patent Application
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a leading pharmaceutical technology company specializing in cannabis-based therapeutics, today announced the filing of a joint application with Ramot at Tel Aviv University Ltd. ("Ramot") to the World Intellectual Property Organization. The application pertains to the development of a novel platform for loading Cannabinoids on Exosomes.
NewsfileInnocan Pharma Reports Successful Results of Efficacy Test for Vaginal Derma Product
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 23, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative wellness products, announced today the successful results of a controlled efficacy test (the "Trial") regarding its vaginal derma product (the "Product").The results of the Trial demonstrate that Innocan's Product, which contains cannabinoids, phytoestrogens, h
NewsfileInnocan Pharma Announces Launch of CBD Veterinary Commercialization Team
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 17, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is excited to announce the launch of its licensing and commercialization strategy work with respect to cannabinoid (CBD) therapy in the veterinary field.Innocan CEO, Iris Bincovich, s
NewsfileInnocan Pharma Announces First Patent Grant in the United States
This is the first fully granted patent of Innocan in the United StatesThe Patent covers Innocan's proprietary cannabis-based pain relief topical This serves as an indication of Innocan's growing intellectual property portfolioHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - March 12, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies
NewsfileInnocan Pharma Reports Clinical Success in Canine Compassionate Care Trial
"Lady", an 11-year-old female dog was presented to Innocan labs suffering from severe autoimmune mediated polyarthritis.Lady was treated with Glycoflex, steroids, and hydrotherapy, but still suffered pain and had difficulty walking more than a few steps.Lady was administered Innocan's liposomal CBD injection and experienced significant improvement, which lasted more than five weeks, indicating the long-acting nature of the liposomal CBD formulation.Herzliya, Israel and Calgary, Alberta--(Newsfil
- Newsfile
Innocan Pharma Provides Annual "State of the Business" Update
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 16, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report an annual "State of the Business" update, including with respect to the company's advancements in Research, Intellectual Property and Commercialization, alongsi
- Newsfile
Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's commercialization of IP in the veterinary field. The principal of Benitz Consulting
NewsfileInnocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth and ar
NewsfileMr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the addition of Givi Topchishvili, to Innocan's Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Giv
NewsfileCanadian Securities Exchange Reports October 2022 Performance Figures
Global Business Development Efforts Continue in Las Vegas and Israel Toronto, Ontario--(Newsfile Corp. - November 15, 2022) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced its market statistics for the month of October 2022.October 2022 Operating StatisticsTrading volume of CSE-listed securities totaled 1.2 billion shares;Trading value of CSE-listed securities was $606 million;CSE issuers completed 54 financings that raised an aggregate $123 million; andThe CSE welco
NewsfileInnocan Pharma Goes Live with Priority(TM) ERP System
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 9, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the successful implementation of Priority Software's Priority™ Enterprise Resource Planning (ERP). The new Priority™ ERP system includes financial, logistics,
NewsfileInnocan Pharma to Participate in IR Labs' Investor Webinar on November 2, 2022
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 25, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce its participation in a webinar titled "Investor Day: Companies Disrupting The World We Live In", co-hosted by IR Labs Inc. ("irlabs") and the NEO Exchange. The
NewsfileInnocan Pharma to Participate in the Luxury Meets CBD Conference on October 20 & 21 in New York
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 13, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan”) a pharmaceutical tech company focusing on developing innovative drug delivery platform technologies comprised with cannabinoids (CBD) is pleased to announce that it will be participating in the Luxury Meets CBD Conference (LMCC) Fall 2022, on October 20th and 21st in New York where Innocan will showcase its patent pending ...
NewsfileInnocan Pharma's Patent Application for Treatment of Psoriasis of the Scalp Reached National Phase
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focusing on developing innovative drug delivery platform technologies comprised with cannabinoids science, is pleased to report an additional milestone with respect to Innocan patent application: PCT application WO2021/240505 that claims Cannabinoids Based Topical Compositions for Treatment of Psori
NewsfileInnocan Pharma Provides an Operational Update
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 21, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, is pleased to provide the following operational update on its key lines of business:Recent development: We are happy to announce that the PCT title as " CANNABIDIOL-CONTAINING COMPOSITIONS AN
NewsfileInnocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment
A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsyThe dog was frequently hospitalized to stop seizure clusters Following treatment using Innocan's LPT (CBD Loaded Liposome Platform), seizures stopped for 9.5 weeksHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 9, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce addit
NewsfileInnocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - September 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical tech company focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, today announced that Iris Bincovich CEO of Innocan Pharma, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New
NewsfileInnocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 30, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to report its financial results for the quarter ended June 30, 2022. Second Quarter 2022 Financial and Operating Highlights (unaudited):Cash balance at end of Q2-22 - USD 7.7M, in Q2-21 - USD 4.6M, an increase of approximately of 70% from the corresponding quarter.Revenues in Q2-22 - USD 415 ...
NewsfileInnocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology
6 dogs suffering from osteoarthritis and lameness demonstrated CBD concentrations 6 weeks after a single injectionPain and well-being scores improved following treatmentHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive partial results in a pilot pain study in dogs using the LPT CBD Liposomal Delivery Platform.Six dogs suffering from osteoarthriti
NewsfileInnocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform
First results from a study on dogs showed close to 100% bioavailability of CBD using Innocan's LPT technologyThis is compared to 6.5-20% bioavailability in humans when administered orallyHerzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce results that approached 100% bioavailability following subcutaneous injection of its CBD proprietary LPT delivery system
NewsfileInnocan Pharma Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 5, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new patent application (PCT) entitled "compositions for treatment of hair loss", claiming priority from an earlier US provisional patent application. The composition developed by Innocan research and development and disclosed in the current PCT can be used to treat and prevent ...